ENDS Flavors: Difference between revisions
No edit summary |
|||
Line 212: | Line 212: | ||
*Signed by 24 experts from around the world | *Signed by 24 experts from around the world | ||
*Covers 12 key points | *Covers 12 key points | ||
===2021: [https://www.sciencedirect.com/science/article/pii/S0306460321003373 Responses to potential nicotine vaping product flavor restrictions among regular vapers using non-tobacco flavors: Findings from the 2020 ITC Smoking and Vaping Survey in Canada, England and the United States]=== | |||
*Conclusion: "At this time, it is not yet clear exactly how NVP flavor bans will play out as they are implemented across national and sub-national jurisdictions. However, by extrapolating from this study, and the other limited studies available, it appears that the outcomes will be mixed and complex. While our study suggests most vapers are opposed to a ban, and some vapers indicated that such a ban would lead to unintended consequences (e.g., taking up cigarette smoking again, or turning to illicit channels), many vapers said that they would be willing to vape available flavors. Thus, it is important for policy makers to weigh the potential for public health consequences, as well as possible benefits." | |||
**Citation: Gravely S, Smith DM, Liber AC, Cummings KM, East KA, Hammond D, Hyland A, O'Connor RJ, Kasza KA, Quah ACK, Loewen R, Martin N, Meng G, Ouimet J, Thompson ME, Boudreau C, McNeill A, Sweanor DT, Fong GT. Responses to potential nicotine vaping product flavor restrictions among regular vapers using non-tobacco flavors: Findings from the 2020 ITC Smoking and Vaping Survey in Canada, England and the United States. Addict Behav. 2022 Feb;125:107152. doi: 10.1016/j.addbeh.2021.107152. Epub 2021 Oct 14. PMID: 34695685; PMCID: PMC9094050. | |||
***Acknowledgment: This study was supported by grants from the US National Cancer Institute (P01 CA200512), the Canadian Institutes of Health Research (FDN-148477), the National Health and Medical Research Council of Australia (APP 1106451). GTF was supported by a Senior Investigator Award from the Ontario Institute for Cancer Research (IA-004) and the Canadian Cancer Society 2020 O. Harold Warwick Prize. AH and RJO are supported by a Tobacco Centers of Regulatory Science US National Cancer Institute grant (U54 CA238110). AL is supported by the Center for the Assessment of Tobacco Regulations (U54CA229974). AM is a National Institute for Health Research (NIHR) Senior Investigator. These funders/supporting agencies had no role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication. Declarations of interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. KMC has served as paid expert witness in litigation filed against cigarette manufacturers. GTF and DH have served as expert witnesses on behalf of governments in litigation involving the tobacco industry. AM is a UK National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the authors and not necessarily those of the NIHR, or the UK Department of Health and Social Care. | |||
===2020: [https://sci-hub.st/https://onlinelibrary.wiley.com/doi/10.1111/add.15235# Association of vaping‐related lung injuries with rates of e‐cigarette and cannabis use across US states]=== <!--T:47--> | ===2020: [https://sci-hub.st/https://onlinelibrary.wiley.com/doi/10.1111/add.15235# Association of vaping‐related lung injuries with rates of e‐cigarette and cannabis use across US states]=== <!--T:47--> |